All In Biotech

Drug Trial Radar · NCT02214628

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the Induction and Maintenance Phase of Therapy

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

101

Actual

Start

Jul 2014

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Ophthotech CorporationIndustry
Sponsor type
Industry
First posted
Aug 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.

Conditions

  • Age-related Macular Degeneration

Interventions

  • Fovista® (anti-PDGF BB) plus anti-VEGFDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subject With Non Serious Adverse Events (Reported by >5% of Subjects)Time frame: 2 years
  2. Number of Subjects With Serious Adverse EventsTime frame: 2 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Sacramento, California

  • Site not named

    Sacramento, California

  • Site not named

    Santa Ana, California

  • Site not named

    Augusta, Georgia

  • Site not named

    Oak Forest, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Jackson, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Ladson, South Carolina

  • Site not named

    Abilene, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.